Vera's kidney drug shows lasting benefit, supporting expanded FDA nod
Vera Therapeutics announced two-year results from a trial of Trutakna in IgA nephropathy, indicating the therapy helped preserve kidney function over time. The company plans to submit these data to the FDA to convert its existing accelerated approval into a full approval. The positive readout strengthens the drug's profile for treating the chronic autoimmune kidney condition.
The latest clinical data for Trutakna, developed by Vera Therapeutics, demonstrates that its protective effect on kidney function endures across a two-year treatment period. These findings are particularly relevant for patients with IgA nephropathy, a chronic autoimmune disorder that progressively damages the kidneys and can lead to end-stage renal disease.
The company intends to use these results to seek a standard FDA approval, upgrading the drug's current accelerated status. A full approval would solidify Trutakna's position in the treatment landscape, offering physicians and patients a validated long-term option for managing this difficult condition and potentially delaying the need for dialysis or transplantation.
If these findings hold up under regulatory review, patients with IgA nephropathy could gain access to a therapy with proven long-term efficacy, potentially slowing disease progression and improving quality of life. For healthcare systems, a durable treatment may reduce the substantial costs associated with advanced kidney failure. However, the true societal impact will depend on accessibility, pricing, and how the drug compares to emerging alternatives in the pipeline.